StockNews.AI
DYN
StockNews.AI
161 days

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

1. Dyne Therapeutics will participate in Stifel's 2025 Virtual CNS Forum. 2. The event is scheduled for March 18, 2025, at 4:00 p.m. ET. 3. A live webcast will be available, highlighting Dyne's innovative therapeutics. 4. Dyne focuses on neuromuscular diseases using its FORCE™ platform. 5. Key clinical and preclinical programs target DM1, DMD, FSHD, and Pompe disease.

3m saved
Insight
Article

FAQ

Why Bullish?

Participation in industry forums can enhance investor interest and visibility, potentially boosting stock price.

How important is it?

The company's advancements in therapeutics and participation in forums signal growth potential, attracting investor interest.

Why Short Term?

Immediate interest is expected from the webcast, but long-term impact depends on product success.

Related Companies

MDGLIBIOSRPT
March 11, 2025 07:30 ET  | Source: Dyne Therapeutics, Inc. WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 4:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook. Contacts: InvestorsMia TobiasDyne Therapeuticsir@dyne-tx.com781-317-0353 MediaStacy NartkerDyne Therapeuticssnartker@dyne-tx.com781-317-1938

Related News